Four-Year OPTIC Data Highlight Durability of Ixo-vec

Carl Danzig, MD, reviews long-term outcomes from the OPTIC trial, including an 86% annualized reduction in anti-VEGF injections through year 4.

By: Carl Danzig, MD, Diana V. Do, MD

Retinal Physician June 18, 2026

Clinical Report: Four-Year OPTIC Data Highlight Durability of Ixo-vec

Overview

The OPTIC trial demonstrates an 86% annualized reduction in anti-VEGF injections through year 4 following a single intravitreal injection of ixo-vec in patients with wet AMD. Safety data indicate minimal inflammation associated with the lower dose of ixo-vec.

Background

Wet age-related macular degeneration (AMD) is a leading cause of vision loss, necessitating frequent anti-VEGF injections for management. The OPTIC trial explores the potential of gene therapy, specifically ixo-vec, to reduce treatment burden. Understanding the long-term outcomes of such therapies is crucial for this patient population.

Data Highlights

No numerical data table available.

Key Findings

The OPTIC trial is a phase 1 multicenter trial focusing on hard-to-treat wet AMD patients.
Patients experienced an average of 10 injections prior to enrolling in the trial.
There was an 86% annualized reduction in anti-VEGF injections in years 2, 3, and 4 after a single injection of ixo-vec.
Safety analysis indicated no serious adverse events such as hypotony or vascular occlusion with the lower dose of ixo-vec.
Minor intraocular inflammation was observed but managed with topical corticosteroids.
The lower dose of ixo-vec showed similar aqueous protein levels compared to the higher dose.

Clinical Implications

The findings from the OPTIC trial indicate that ixo-vec may reduce the frequency of anti-VEGF injections. The safety profile observed with the lower dose supports its further evaluation in clinical trials.

Conclusion

The long-term data from the OPTIC trial provide insights into the durability and safety outcomes associated with ixo-vec in the treatment of wet AMD.

PentaVision

Retinal Physician